HealthTech
Perzea Launch Strengthens Hetero Healthcare’s Oncology Leadership Through Partnership with Enzene Biosciences
[ad_1]
Hetero Healthcare and Enzene launched Perzea, India’s most affordable Pertuzumab biosimilar
Hyderabad (Telangana) [India], September 25: Hetero Healthcare Limited, in strategic collaboration with Enzene Biosciences, has launched Perzea, India’s most affordable Pertuzumab biosimilar. The introduction of this targeted therapy for HER2-positive breast cancer demonstrates the synergy between two healthcare leaders committed to advanced cancer treatment accessibility.
Innovation Meets Affordability
Pertuzumab plays a vital role in the…
[ad_2]
Source link
Continue Reading